Oncotype DX Breast Cancer Testing
East Sussex Healthcare NHS Trust · Awarded
- Buyer
- East Sussex Healthcare NHS Trust
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Professional Services
- Reference
- UK-CFA-ocds-b5fd17-6952487a-f7d5-42df-ae7a-052feb2a20e7
- Published
- 2026-03-03
- Deadline
- 2026-02-04
Tender summary
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access